Page 1 of 23

F.C. ODDS - PUBLICATIONS

Books/Monographs, etc.

2002 Odds, F.C., Johnson, E.R., Barnes, R.A. (eds) AmBisome®: An International Workshop. Journal of Antimicrobial Chemotherapy 49 (suppl 1).

1997 Vanden Bossche, H., Odds, F.C., Stevens, D.A. (eds.) Host-fungus interplay. National Foundation for Infectious Diseases, Bethesda, MD.

1996 Kibbler, C.C., Mackenzie, D.W.R., Odds, F.C. (eds.) Principles and practice of clinical mycology. J. Wiley & Sons, Chichester.

1993 Vanden Bossche, H., Odds, F.C., Kerridge, D. (eds.) Dimorphic fungi in biology and medicine. Plenum Press, New York and London.

1989 Kobayashi, G.S., Odds, F.C. (guest editors) Current perspectives on antifungal susceptibility testing. Scientific Therapeutics Information, Inc., Springfield, New Jersey (30 pages).

1988 Odds, F.C. Candida and candidosis, 2nd ed. (489 pages, 5790 refs.) Bailliere-Tindall, London.

1979 Odds, F.C. Candida and candidosis. (382 pages, 2265 refs.). Leicester University Press, Leicester. (Published in North America by University Park Press, Baltimore, MD, U.S.A.).

1976 E.G.V. Evans (ed.) Serology of fungal infection and farmer's lung disease. British Society for Mycopathology, Leeds. (Co-author as member of Working Party on fungal antigens.).

Articles/book chapters2008 Odds, F.C., Jacobsen, M.D. Multi-locus sequence typing of pathogenic

Candida species. Eukaryotic Cell (in press).2008 Naglik, J., Fidel, P., Odds, F.C. Animal models of mucosal Candida

infection. FEMS Microbiol. Lett. (in press).2007 Odds, F.C. The evolution of pathogenic Candida species. In Baquero, F.,

Nombela, C., Cassel, G.H., Gutierrez, J.A. (eds.) Evolutionary Biology of Bacterial and Fungal Pathogens. pp565–578, ASM Press, Washington.

2007 Brown, A.J.P., Odds, F.C., Gow, N.A.R. Infection-related gene expression in Candida albicans. Current Opinion in Microbiology 10, 307–313.

2006 Odds, F.C., Gow, N.A.R., Brown, A.J.P. Towards a molecular understanding of Candida albicans virulence. In Heitman, J., Filler, S., Mitchell, A. (eds.) Molecular Principles of Fungal Pathogenesis, pp. 305–320. ASM Press, Washington, DC.

2006 Odds, F.C. Genomics, molecular targets and the discovery of antifungal drugs. Revista Iberoamericana de Micología 22, 229–237.

2006 Odds, F.C. Drug evaluation: BAL-8557 — a novel broad-spectrum triazole antifungal. Current Opinion in Investigational Drugs 7, 766–772.

2005 Odds, F.C. Antifungal agents: resistance and rational use. In I.M. Gould and J.W.M. Van der Meer (eds) Antibiotic policies: theory and practice, pp. 311–330. Kluwer Academic/Plenum Publishers, New York.

2004 Odds, F.C., Brown, A.J.P., Gow, N.A.R. Candida albicans genome sequence: a platform for genomics in the absence of genetics. Genome Biology 5, 230.1–230.3.

Page 2 of 23

2003 Odds, F.C., Hube, B., Calderone, R.A., Nombéla, C. Virulence in Candida species: views and suggestions from a peer-group workshop ASM News 69, 54–55.

2003 Odds, F.C., Brown, A.J.P., Gow, N.A.R. Antifungal agents: mechanisms of action. Trends in Microbiology 11, 272–279.

2003 Odds, F.C. Synergy, antagonism, and what the chequerboard puts between them (editorial). Journal of Antimicrobial Chemotherapy 52, 1.

2003 Odds, F.C. Reflections on the question: What does molecular mycology have to do with the clinician treating the patient? Medical Mycology 41, 1–6.

2003 Odds, F.C. Editorial commentary: fluconazole plus amphotericin B combinations are not contraindicated and may add benefit for treatment of candidemia. Clinical Infectious Diseases 36, 1229–1230.

2003 Odds, F.C. Coccidioidomycosis: flying conidia and severed heads. The Mycologist 17, 37–40.

2003 Odds, F.C. Antifungal agents: their diversity and increasing sophistication. The Mycologist 17, 51–55.

2002 Sanglard, D., Odds, F.C. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. The Lancet Infectious Diseases 2, 73–85.

2002 Gow, N.A.R., Brown, A.J.P., Odds, F.C. Fungal morphogenesis and host invasion. Current Opinion in Microbiology 5, 366–371.

2001 Walsh, T.J., Viviani, M.-A., Arathoon, E., Chiou, C., Ghannoum, M., Groll, A.H., Odds, F.C. New targets and delivery systems for antifungal therapy. Medical Mycology 38 (suppl. 1), 335–347.

2001 Rex, J.H., Pfaller, M.A., Walsh, T.J., Chaturvedi, V. Espinel-Ingroff, A., Ghannoum, M.A., Gosey, L.L., Odds, F.C., Rinaldi, M.G., Sheehan, D.J., Warnock, D.W. Antifungal susceptibility testing: practical aspects and current challenges. Clinical Microbiology Reviews 14, 643–658.

2001 Odds, F.C., Gow, N.A.R., Brown, A.J.P. Fungal virulence studies come of age. Genome Biology 2, 1009.1–1009.4.

2001 Odds, F.C. Sordarin antifungal agents. Expert Opinion on Therapeutic Patents 11, 283–294.

2001 Odds, F.C. In vitro susceptibility testing of antifungal agents: are the results of relevance to clinical decision making? In: The Effective Prevention and Management of Systemic Fungal Infection in Haematological Malignancy (A. Prentice, T. Rogers, A. Miles, eds.). UK Key Advances in Clinical Practice Series 2001; Aesculapius Medical Press, pp. 111–116.

2001 Finquelievich, J.L., Odds, F.C., Queiroz-Telles, F., Wheat, L.J. New advances in antifungal treatment. Medical Mycology 38 (suppl. 1), 317–322.

2000 Odds, F.C., Brown, A.J.P., Gow, N.A.R. Might Candida albicans be made to mate after all? Trends in Microbiology 8, 4–6.

2000 Odds, F.C. Pathogenic fungi in the 21st century. Trends in Microbiology 8, 201–208.

2000 Odds, F.C. Are molecular methods the optimum route to new antimicrobial agents? In Andrew, P.W., Oyston, P., Smith, G.L., Stewart-Tull, D.E. (eds). Fighting Infection in the 21st Century pages 237–258. Blackwell Science, Oxford.

Page 3 of 23

2000 Gow, N.A.R., Brown, A.J.P., Odds, F.C. Candida’s arranged marriage. Science 289, 256–257.

1999 Odds, F.C. Editorial overview [editorial]. Current Opinion in Anti-infective Investigational Drugs 1, 296.

1998 Odds, F.C. Should resistance to azole antifungals in vitro be interpreted as predicting clinical non-response. DrugResistance Updates 1, 11–15.

1998 Odds, F.C. Fungal dimorphism [editorial]. Journal de Mycologie Médicale 8, 55–56.

1998 Hube, B, Sanglard, D., Schaller, M., Ibrahim, A., Odds, F.C., Gow, N.A.R. What are the functions of six different genes encoding secreted proteinases in Candida albicans. Mycoses 41 (suppl. 1), 47–50.

1998 Hube, B, Rüchel, R., Monod, M., Sanglard, D., Odds, F.C. Functional aspects of secreted Candida proteinases. Advances in Experimental Biology and Medicine 436, 339–344.

1997 Odds, F.C. The role of antifungal drug evaluation in vitro in the treatment of mycoses. Advances in Medical Mycology (in press).

1997 Odds, F.C. Switch of phenotype as an escape mechanism of the intruder. Mycoses 40 (suppl. 2), 9–12.

1997 Odds, F.C. Strain typing of Candida albicans. In Jacobs, P., Nall, L. (eds.) Biomedical mycology pages 357–374. Marcel Dekker, Inc., New York.

1997 Odds, F.C. Personal opinion: can antifungal sensitivity tests predict clinical treatment outcomes? Revista Iberoamericana de Micología 14, 83–84.

1997 Odds, F.C. Mycology in oral pathology. Acta Stomatologica Belgica 94, 75–80.

1996 Overdijk, B., Van Steijn, G.J., Odds, F.C. Chitinase levels in guinea pig blood are increased in experimentally induced aspergillosis. In: Muzzarelli, R.A.A. (ed) Chitin Enzymology, vol. 2, pp. 21–35. Atec Edizioni, Italy.

1996 Odds, F.C., Rinaldi, M.G. Nomenclature of fungal diseases. In Borgers, M., Hay, R.J., Rinaldi, M.G. (eds). Current Topics in Medical Mycology volume 6, pp. 33–46. JR Prous, Barcelona.

1996 Odds, F.C. The fungal kingdom: essentials of medical mycology. In Kibbler, C.C., Mackenzie, D.W.R.M., Odds, F.C. (eds). Principles and Practice of Clinical Mycology pages 1–6. J. Wiley & Sons, Chichester.

1996 Odds, F.C. Medical mycology and the millenium. Revista Iberoamericana de Micología 13, S69–S70.

1996 Odds, F.C. Epidemiological shifts in opportunistic and nosocomial Candida infection: mycological aspects. International Journal of Antimicrobial Agents 6, 141–144.

1996 Odds, F.C. Antifungal therapy. In Kibbler, C.C., Mackenzie, D.W.R.M., Odds, F.C. (eds). Principles and Practice of Clinical Mycology pages 35–48. J. Wiley & Sons, Chichester.

1995 Vanden Bossche, H., Warnock, D.W., Dupont, B., Kerridge, D., Gupta, S.S., Improvisi, L., Marichal, P., Odds, F.C., Provost, F., Ronin, O.

Page 4 of 23

Mechanisms and clinical impact of antifungal drug resistance. Journal of Medical and Veterinary Mycology 32 (spl 1), 189–202.

1995 Odds, F.C. Resistencia a los agentes antifúngicos de las levaduras de interés clinico. Revista Clinica Española 195, 56–57.

1995 Odds, F.C. Les agents antifungiques, leur passé, leur présent et leur avenir. Bulletin de la Société Françcaise de Microbiologie Médicale 10, 285–293.

1995 Odds, F.C. Cambios en la epidemiología de las infecciones oportunistas por Candida. Revista Clinica Española 195, 1–3.

1994 Vanden Bossche, H., Marichal, P., Odds, F.C. Molecular mechanisms of drug resistance in fungi. Trends in Microbiology 2, 393-400.

1994 Odds, F.C. Systemic mycoses and their management. Forum (in press).1994 Odds, F.C. Pathogenesis of Candida infections. Journal of the American

Academy of Dermatology 31, S2-S5.1994 Odds, F.C. Nomenclatura delle micosi, In L. Ajello, C. Farina, A.

Mazzoni, G. Picerno (eds) Fondamenti di micologia clinica Associazione Microbiologi Clinici Italiani, Milano, pp. 103-116.

1994 Odds, F.C. New aspects of the epidemiology of Candida infections. In Nelwan, R.H.H. (ed). Proceedings of the 3rd Western Pacific Congress on Chemotherapy and Infectious Diseases — Bali 1992 pages 265–269.

1994 Odds, F.C. Laboratory evaluation of antifungal agents in vitro. Infectious Diseases in Clinical Practice 3 (suppl. 2), S90–S96.

1994 Odds, F.C. Implications of resistance and trends in the epidemiology of mycoses. Clinician 11, 14–18.

1994 Odds, F.C. Implications of resistance and trends in the epidemiology of mycoses. Clinician 11, 14–18.

1994 Odds, F.C. Candida species and virulence. ASM News 60, 313-318.1994 Odds, F.C. Candida albicans, the life and times of a pathogenic yeast.

Presidential address. Journal of Medical and Veterinary Mycology 32 (spl 1), 1–8.

1994 Agabian, N., Odds, F.C., Poulain, D., Soll, D.R., White, T.C. Pathogenesis of invasive candidiasis. Journal of Medical and Veterinary Mycology 32 (spl 1), 229–238.

1993 Odds, F.C. & Van Cutsem, J. Itraconazole — preclinical data in vitro and in vivo in cutaneous and other superficial mycoses. In J. Rippon & R.P. Fromtling (eds) Cutaneous Antifungal Agents, pp. 251–261.

1993 Odds, F.C. Vulvovaginale Candida-Infektion: Aspekte der Epidemiologie, Pathogenese und Behandlung. International Journal of Feto-Maternal Medicine 6 (suppl 1), 19-24.

1993 Odds, F.C. Vulvovaginal Candida infection: aspects of epidemiology, pathogenesis and management. International Journal of Experimental and Clinical Chemotherapy 5, 65–72.

1993 Odds, F.C. Spectrum of orally active antifungals. Journal of the European Academy of Dermatology and Venereology. 2 (suppl 1), S12-S18.

Page 5 of 23

1993 Odds, F.C. Spectrum of orally active antifungals. In W.H.C. Burgdorf & S.I.Katz (eds) Dermatology: progress and perspectives. Parthenon Publishing Group, New York, pp. 277–279.

1993 Odds, F.C. Resistance of yeasts to azole-derivative antifungals. Journal of Antimicrobial Chemotherapy 31, 463-471.

1993 Odds, F.C. Quantification of Candida morphology in vitro and in vivo. In H. Vanden Bossche, F.C. Odds and D. Kerridge (eds) Dimorphic fungi in biology and medicine Plenum Press, New York and London, pp. 145–152.

1993 Odds, F.C. Morphological change in Candida albicans. Jpn. J. Med. Mycol. 34, 99-111.

1993 Odds, F.C. Itraconazole — a new oral antifungal agent with a very broad spectrum of activity in superficial and systemic mycoses. Jourrnal of Dermatological Science 5, 65-72.

1993 Odds, F.C. Epidemiology and diagnosis of vulvovaginal Candida infections. International Journal of Feto-Maternal Medicine 5, 151-153.

1992 Odds, F.C., Brawner, D.L., Staudinger, J., Magee, P.T. & Soll, D.R. Typing of Candida albicans strains. Journal of Medical and Veterinary Mycology 30 (suppl 1), 87-94.

1992 Odds, F.C. Candida infection in AIDS patients. International Journal of STD & AIDS 3, 157-160.

1991 Odds, F.C. Sabouraud('s) agar. Journal of Medical and Veterinary Mycology 29, 355-359.

1991 Hube, B., Turver, C.J., Odds, F.C., Eiffert, H., Boulnois, G.J., Köchel, H., Rüchel, R. Identifizierung, Klonierung und Charakterisierung des Gens der sekretorischen Aspartat-Protease von Candida albicans. Mycoses 34 (suppl. 1), 59–61.

1991 Odds, F.C. Potential for penetration of passive barriers to fungal invasion in humans. In: G.T. Cole & H.C. Hoch (eds.) The fungal spore and disease initiation in plants and animals, pp. 287-295. Plenum Press, New York.

1991 Odds, F.C. Perspective of the application of molecular biology techniques in the study of Candida. In: E. Tumbay, H.P.R. Seeliger & O. Ang (eds.) Candida and candidamycosis. FEMS Symposium No. 50., pp. 5–11. Plenum Press, New York.

1990 Odds, F.C., Schmid, J. & Soll, D.R. Epidemiology of Candida infections in AIDS. In H. Vanden Bossche, D.W.R. Mackenzie, G. Cauwenbergh, J. Van Cutsem, E. Drouhet & B. Dupont (eds.) Mycoses in AIDS Patients, pp. 67-74. Plenum Press, New York.

1990 Odds, F.C. Role of in-vitro evaluation for therapeutic decisions in candidosis. In: Therapy of candidosis: from screening to clinical evaluation (Proceedings of a satellite symposium of the FEMS Symposium on Candida and candidamycosis) pp. 44-47. Janssen Pharmaceutica, Belgium.

1990 Odds, F.C. Biologie moléculaire dans l'étude de Candida. Bulletin de la Société Française de Mycologie Médicale 19, 5-12.

Page 6 of 23

1989 Odds, F.C. Facteurs d'inhibition relative: une nouvelle approche de l'evaluation in vitro des antibiotiques antifongiques. Annales de Dermatologie et Véneréologie 116 (suppl. 1), 10-12.

1989 Odds, F.C. Candidiasis cutánea y mucosa: Etiología y patogenia. Drugs of Today 25 (suppl. 9), 33-37.

1987 Odds, F.C. Progrés récents dans la biologie des Candida. Annales de Biologie Clinique 45, 553-557.

1987 Odds, F.C. Candida infections: an overview. CRC Critical Reviews in Microbiology 15, 1-6.

1986 Odds, F.C. Summing up and outlook. In: K. Iwata & H. Vanden Bossche (eds.) In vitro and in vivo evaluation of antifungal agents, 299-303. Elsevier Science Publishers B.V., Amsterdam.

1986 Odds, F.C. A survey of old and new antifungal tests in vitro. In: K. Iwata & H. Vanden Bossche (eds.) In vitro and in vivo evaluation of antifungal agents, 13-19. Elsevier Science Publishers B.V., Amsterdam.

1985 Odds, F.C. Morphogenesis in Candida albicans. CRC Critical Reviews in Microbiology 12, 45-93.

1985 Odds, F.C. Laboratory tests for the activity of imidazole and triazole antifungal agents in vitro. Seminars in Dermatology 4, 260-269.

1985 Odds, F.C. Candida albicans proteinase as a virulence factor in the pathogenesis of Candida infections. Zentralblatt fur Bakteriologie und Hygiene A 260, 539-542.

1985 Odds, F.C. Biotyping of medically important fungi. In: M.R. McGinnis (ed.) Current Topics in Medical Mycology 1, 155-171.

1984 Odds, F.C. Ecology and epidemiology of Candida species. Zentralblatt fur Bakteriologie A 287, 207-212.

1981 Odds, F.C. The pathogenesis of candidosis. Hospital Update 7, 935-945.1981 Odds, F.C. Studies with ketoconazole in vitro. Clinical Research Reviews

1, 173-175.1977 Odds, F.C. Management and treatment of candidosis. Medical News,

March 2, 10-11.

Page 7 of 23

Original papers in peer-reviewed scientific journals

2008 Jacobsen, M.D., Davidson, A.D., Li, S.-Y., Shaw, D.J., Gow, N.A.R., OddS, F.C. Molecular phylogenetic analysis of Candida tropicalis isolates by multi-locus sequence typing. Fungal Genetics and Biology (in press).

2008 Jacobsen, M.D., Boekhout, T., Odds, F.C. Multilocus sequence typing reveals synonymy and indicates differences between Candida albicans and Candida stellatoidea. FEMS Yeast Research (in press).

2008 De Pauw, B., Walsh, T.J., Donnelly, J.P., Stevens, D.A., Edwards, J.E., Calandra, T., Pappas, P.G., Maertens, J., Lortholary, O., Kauffman, C.A., Denning, D.W., Patterson, T.F., Maschmeyer, G., Bille, J., Dismukes, W.E., Herbrecht, R., Hope, W.W. Kibbler, C.C., Kullberg, B.-J., Marr, K.A., Muñoz, P., Odds, F.C., Perfect, J.R., Restrepo, A., Ruhnke, M., Segal, B.H., Sobel, J.D., Sorrell, T.C., Viscoli, C., Wingard, J.R., Zaoutis, T., Bennett, J.E. Revised definitions of the EORTC/MSG Consensus 1 Group for invasive fungal diseases. Clinical Infectious Diseases (in press).

2008 Takakura, S., Ichiyama, S., Bain, J.M., Davidson, A.D., Jacobsen, M.D., Shaw, D.J., Gow, N.A.R., Odds, F.C. Comparison of Candida albicans strain types among isolates from three countries. International Journal of Medical Microbiology (in press).

2008 Strijbis, K., van Roermund, C.W.T., Visser, W.F., Mol, E.C., van den Burg, J., MacCallum, D.M., Odds, F.C., Paramonova, E., Krom, B.P., Distel, B. Carnitine-dependent transport of acetyl-CoA in Candida albicans is essential for growth on non-fermentable carbon sources and contributes to biofilm formation. Eukaryotic Cell 7, 610–618.

2007 Odds, F.C., Hanson, M.F., Davidson, A.D., Jacobsen, M.D., Wright, P., Whyte, J.A., Gow, N.A.R., Jones, B.L. One-year prospective survey of Candida bloodstream infections in Scotland. Journal of Medical Microbiology 56, 1066–1075.

2007 Odds, F.C., Bougnoux, M.-E., Shaw, D.J., Bain, J.M., Davidson, A.D., Diogo, D., Jacobsen, M.D., Lecomte, M., Li, S.-Y., Tavanti, A., Maiden, M.C.J., Gow, N.A.R., d’Enfert, C. Molecular phylogenetics of Candida albicans. Eukaryotic Cell 6, 1041–1052.

2007 Mora-Montes, H., Bates, S., Netea, M.G., Díaz-Jiménez, D.F., López-Romero, E., Zinker, S., Ponce-Noyola, P., Kullberg, B.-J., Brown, A.J.P., Odds, F.C., Flores-Carreón, A., Gow, N.A.R. The endoplasmic reticulum α-glycosidases of Candida albicans are required for N-glycosylation, cell wall integrity and normal host-fungus interaction. Eukaryotic Cell 6, 2184–2193.

2007 Kunze, D., MacCallum, D., Odds, F.C., Hube, B. Multiple functions of DOA1 in Candida albicans. Microbiology 153, 1026–1041.

2007 Jacobsen, M.D., Whyte, J.A., Odds, F.C. Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro Antimicrobial Agents and Chemotherapy 51, 1882–1884.

2007 Jacobsen, M.D., Gow, N.A.R., Maiden, M.C.J., Shaw, D.J., Odds, F.C. Strain typing and determination of population structure of Candida krusei by multilocus sequence typing. Journal of Clinical Microbiology 45, 317–323.

Page 8 of 23

2007 Jacobsen, M.D., Davidson, A.D., Li, S.-Y., Shaw, D.J., Gow, N.A.R., OddS, F.C. Molecular phylogenetic analysis of Candida tropicalis isolates by multi-locus sequence typing. Fungal Genetics and Biology (in press).

2007 Jacobsen, M.D., Boekhout, T., Odds, F.C. Multilocus sequence typing reveals synonymy and indicates differences between Candida albicans and Candida stellatoidea. FEMS Yeast Research (in press).

2007 Gow, N.A.R., Netea, M.G., Munro, C.A., Ferwerda, G., Bates, S., Mora-Montes, H., Walker, L., Jansen, T., Jacobs, L., Tsoni, V., Brown, G.D., Odds, F.C., Van der Meer, J.W.M., Brown, A.J.P., Kullberg, B.-J. Recognition of Candida albicans β-glucan by dectin-1 induces cytokines and has non-redundant effects on the activation of innate immunity. Journal of Infectious Diseases 196, 1566–1571.

2007 Enjalbert, B., MacCallum, D.M., Odds, F.C., Brown, A.J.P. Niche-specific activation of the oxidative stress response by the pathogenic fungus Candida albicans. Infection and Immunity 75, 2143–2151.

2007 De Pauw, B., Walsh, T.J., Donnelly, J.P., Stevens, D.A., Edwards, J.E., Calandra, T., Pappas, P.G., Maertens, J., Lortholary, O., Kauffman, C.A., Denning, D.W., Patterson, T.F., Maschmeyer, G., Bille, J., Dismukes, W.E., Herbrecht, R., Hope, W.W. Kibbler, C.C., Kullberg, B.-J., Marr, K.A., Muñoz, P., Odds, F.C., Perfect, J.R., Restrepo, A., Ruhnke, M., Segal, B.H., Sobel, J.D., Sorrell, T.C., Viscoli, C., Wingard, J.R., Zaoutis, T., Bennett, J.E. Revised definitions of the EORTC/MSG Consensus 1 Group for invasive fungal diseases. Clinical Infectious Diseases (in press).

2007 Chaves, G.M., Bates, S., MacCallum, D.M., Odds, F.C. Candida albicans GRX2, encoding a putative glutaredoxin, is required for virulence in a murine model. Genetics and Molecular Research 6, 1051–1063.

2007 Bates, S., de la Rosa, J.M., MacCallum, D.M., Brown, A.J.P., Gow, N.A.R., Odds, F.C. Candida albicans Iff11, a secreted protein required for cell wall structure and virulence. Infection and Immunity 75, 2922–2928.

2007 Barelle, C.J., Duncan, V.M.S., Brown, A.J.P., Gow, N.A.R., Odds, F.C. Azole antifungals induce upregulations of SAP4, SAP5 and SAP6 secreted proteinase genes in filamentous Candida albicans cells in vitro and in vivo. Journal of Antimicrobial Chemotherapy 61, 315–322.

2007 Bain, J.M., Tavanti, A., Davidson, A.D., Jacobsen, M.D., Shaw, D., Gow, N.A.R., Odds, F.C. Multilocus sequence typing of the pathogenic fungus Aspergillus fumigatus. Journal of Clinical Microbiology 45, 1469–1477.

2007 Argimón, S., Wishart, J.A., Leng, R., Macaskill, S., Mavor, A., Alexandris, T., Nicholls, S., Knight, A.W., Enjalbert, B., Walmsley, R., Odds, F.C., Gow, N.A.R., Brown, A.J.P. Developmental regulation of an adhesin gene during cellular morphogenesis in the fungal pathogen Candida albicans. Eukaryotic Cell 6, 682–692.

2006 Piekarska, K., Mol, E., van den Berg, M., Hardy, G., van den Burg, J., van Roermun, C., MacCallum, D., Odds, F., Distel, B. Peroxisomal fatty acid -oxidation is not essential for virulence of Candida albicans. Eukaryotic Cell 5, 1847–1856.

2006 Pfaller, M.A., Diekema, D.J., Rex, J.H., Espinel-Ingroff, A, Johnson, E.M., Andes, D., Chaturvedi, V., Ghannoum, M.A., Odds, F.C., Rinaldi, M.G., Sheehan, D.J., Troke, P., Walsh, T.J., Warnock, D.W.

Page 9 of 23

Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. Journal of Clinical Microbiology 44, 819–826.

2006 Odds, F.C., Davidson, A.D., Jacobsen, M. D., Tavanti, A., Whyte, J.A., Kibbler, C.C., Ellis, D.H., Maiden, M.C.J., Shaw, D.J., Gow, N.A.R. Candida albicans strain maintenance, replacement, and microvariation demonstrated by multilocus sequence typing. Journal of Clinical Microbiology 44, 3647–3658.

2006 MacCallum, D.M., Findon, H., Kenny, C.C. Butler, G., Haynes, K., Odds, F.C. Different consequences of ACE2 and SWI5 gene disruptions for virulence of pathogenic and nonpathogenic yeasts. Infection and Immunity 74, 5244–5248.

2006 Chen, K.-W., Chen, Y.-C., Lo, H.-J., Odds, F.C., Wang, T.-H., Lin, C.-Y., Li, S.-Y. Multilocus sequence typing for analyses of clonality of Candida albicans strains in Taiwan. Journal of Clinical Microbiology 44, 2172–2178.

2006 Bates, S. Hughes, H.B., Munro, C.A., Thomas, W.P.H., MacCallum, D.M., Bertram, G., Atrih, A., Ferguson, M.A.J., Brown, A.J.P., Odds, F.C., Gow, N.A.R. Outer chain N-glycans are required for cell wall integrity and virulence of Candida albicans. Journal of Biological Chemistry 281, 90–98.

2006 Barelle, C.J., Manson, C.L., MacCallum, D.M., Gow, N.A.R. Odds, F.C. Brown, A.J.P. Niche-specific regulation of central metabolic pathways in a fungal pathogen. Cellular Microbiology 8, 961–971.

2005 Tournu, H., Tripathi, G., Bertram, G., Macaskill, S., Mavor, A., Walker, L., Odds, F.C., Gow, N.A.R., Brown, A.J.P. . Global regulation of the protein kinase Gcn2 in the human pathogen Candida albicans. Eukaryotic Cell 4, 1687–1696.

2005 Tavanti, A., Davidson, A.D., Johnson, E.M., Maiden, M.C.J., Shaw, D.J., Gow, N.A.R., Odds, F.C. Multilocus sequence typing for differentiation of strains of Candida tropicalis. Journal of Clinical Microbiology 43, 5593–5600.

2005 Tavanti, A., Davidson, A.D., Gow, N.A.R., Maiden, M.C.J., Odds, F.C. Candida orthopsilosis and Candida metapsilosis, spp. nov., to replace Candida parapsilosis groups II and III. Journal of Clinical Microbiology 43, 284–292.

2005 Tavanti, A., Davidson, A.D., Fordyce, M.J., Gow, N.A.R., Maiden, M.C.J., Odds, F.C. Candida albicans: populations and properties determined by multi-locus sequence typing. Journal of Clinical Microbiology 43, 5601–5613.

2005 Munro, C.A., Bates, S., Buurman, E.T., Hughes, H.B., MacCallum, D.M., Bertram, G., Atrih, A., Ferguson, M.A.J., Bain, J.M., Brand, A., Hamilton, S., Westwater, C., Thomson, L.M., Brown, A.J.P., Odds, F.C., Gow, N.A.R. Mnt1p and Mnt2p of Candida albicans are partially redundant -1,2-mannosyltranferases that participate in O-linked mannosylation and are required for adhesion and virulence. Journal of Biological Chemistry 280, 1051–1060.

2005 Meerpoel, L., Backx, L.J.J., Van der Veken, L.J.E., Heeres, J., Corens, D., De Groot, A., Odds, F.C., Van Gerven, F., Woestenborghs, F.A.A., Van Breda, A., Oris, M., van Dorsselaer, P., Willemsens, G.H.M.,

Page 10 of 23

Vermuyten, K.J.P., Marichal, P.J.M.G., Vanden Bossche, H.F., Ausma, J., Borgers, M. Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. Journal of Medicinal Chemistry 48, 2184–2193.

2005 MacCallum, D.M., Whyte, J.A., Odds, F.C. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrobial Agents and Chemotherapy 49, 3697–3701.

2005 MacCallum, D.M., Odds, F.C. Temporal events in the intravenous challenge model for experimental Candida albicans infections in female mice. Mycoses 48, 151–161.

2005 Kunze, D., Melzer, I., Bennett, D., Sanglard, D., MacCallum, D., Nörskau, J., Coleman, D.C., Odds, F.C., Schäfer, W., Hube, B. Functional analysis of the phospholipase C gene CaPLC1 and two unusual phopholipase C genes, CaPLC2 and CaPLC3, of Candida albicans. Microbiology 151, 3381–3394.

2005 Fradin, C., MacCallum, D.M., Odds, F.C., Hube, B. Granulocytes govern the transcriptional response, morphology and proliferation of Candida albicans in human blood. Molecular Microbiology 56, 397–415.

2005 Copping, V.M.S., Barelle, C.J., Hube, B., Gow, N.A.R., Brown, A.J.P., Odds, F.C. Exposure of Candida albicans to antifungal agents affects expression of SAP2 and SAP9 secreted proteinase genes. Journal of Antimicrobial Chemotherapy 55, 645–654.

2005 Bates, S., MacCallum, D.M., Bertram, G., Munro, C.A., Hughes, H.B. Buurman, E.T., Brown, A.J.P., Odds, F.C., Gow, N.A.R. Candida albicans Pmr1p, a secretory pathway Ca2+/Mn2+ P-type ATPase, is required for glycosylation and virulence. Journal of Biological Chemistry 280, 23408–23415.

2005 Albrecht, A., Felk, A., Pichova, I., Naglik, J.R., Schaller, M., de Groot, P., MacCallum, D., Odds, F.C., Schäfer, W., Klis, F., Monod, M., Hube, B. Glycosylphosphatidylinositol-anchored proteases of Candida albicans target proteins necessary for both cellular processes and host-pathogen interactions. Journal of Biological Chemistry 281, 688–694.

2004 Vanden Bossche, H., Ausma, J., Bohets, H., Vermuyten, K., Willemsens, G., Marichal, P., Meerpoel, L., Odds, F., Borgers, M. The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp. and Microsporum canis. Antimicrobial Agents and Chemotherapy 48, 3272–3278.

2004 Tavanti, A., Gow, N.A.R., Maiden, M.J., Odds, F.C., Shaw, D.J. Genetic evidence for recombination in Candida albicans based on haplotype analysis. Fungal Genetics and Biology 41, 553–562.

2004 Sendid, B., Jouault, T., Coudriau, R., Camus, D., Odds, F., Tabouret, M., Poulain, D. Increased sensitivity of mannanemia detection tests by joint detection of alpha- and beta-linked oligomannosides during experimental and human systemic candidiasis. Journal of Clinical Microbiology 42, 164–171.

2004 Odds, F.C., Motyl, M., Andrade, R., Bille, J., Cantón, E., Cuenca-Estrella, M., Davidson, A., Durussel, C., Ellis, D., Foraker, E., Fothergill, A.W., Ghannoum, M.A., Giacobbe, R.A., Gobernado, M., Handke, R., Laverdière, M., Lee-Yang, W., Merz, W.G. Ostrosky-Zeichner, L., Pemán, J., Perea1, S., Perfect, J.R., Pfaller, M.A., Proia,

Page 11 of 23

L., Rex, J.H., Rinaldi, M.G., Rodriguez-Tudela, J.-L., Schell, W., Shields, C., Sutton, D.A., Verweij, P.E., Warnock, D.W. Susceptibility testing with caspofungin against Candida and Aspergillus species: an inter-laboratory comparison. Journal of Clinical Microbiology 42, 3475–3482.

2004 Odds, F.C., Ausma, J., Van Gerven, F., Woestenborghs, F., Meerpoel, L., Heeres, J., Vanden Bossche, H., Borgers M. In vitro and in vivo activities of the novel azole antifungal agent R126638. Antimicrobial Agents and Chemotherapy 48, 388-391.

2004 MacCallum, D.M., Odds, F.C. Safety aspects of working with Candida albicans-infected mice. Medical Mycology 42, 305-309.

2004 MacCallum, D.M., Odds, F.C. Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection. Antimicrobial Agents and Chemotherapy 48, 4911–4914.

2004 Kelly, M.T., MacCallum, D.M., Odds, F.C., Brown, A.J., Butler, G. The Candida albicans CaACE2 gene affects morphogenesis, adherence and virulence. Molecular Microbiology 53, 969–983.

2004 Hobson, R.P., Munro, C.A., Bates, S., MacCallum, D.M., Cutler, J.E., Heinsbroek, S.E.M., Brown, G.D., Odds, F.C., Gow, N.A.R. Loss of cell wall mannosylphosphate in Candida albicans does not influence macrophage recognition. Journal of Biological Chemistry 279, 39628–39635.

2004 Galán, A., Casanova, M., Murgui, A., MacCallum, D.M., Odds, F.C., Gow, N.A.R., Martínez, J.P. The Candida albicans pH-regulated KER1 gene encodes a lysine/glutamic acid rich plasma-membrane protein that is involved in cell aggregation. Microbiology 150, 2641-2651.

2004 Brand, A., MacCallum, D.M., Brown, A.J.P., Gow, N.A.R., Odds, F.C. Ectopic expression of URA3 can influence the virulence phenotypes and proteome of Candida albicans but can be overcome by targeted re-integration of URA3 at the RPS10 locus. Eukaryotic Cell 3, 900–909.

2004 Barelle, C.J., Manson, C.L., MacCallum, D.M., Odds, F.C., Gow, N.A.R., Brown, A.J.P. GFP as a quantitative reporter of gene regulation in Candida albicans. Yeast 21, 333–340.

2003 Tavanti, A., Gow, N.A.R., Senesi, S., Maiden, M.C., Odds, F.C. Optimization and validation of multi-locus sequence typing for Candida albicans. Journal of Clinical Microbiology 41, 3765–3776.

2003 Bougnoux, M.-E., Tavanti, A., Couchier, C., Gow, N.A.R., Magnier, A., Davidson, A.D., Maiden, M.C.J., d’Enfert, C., Odds, F.C. Collaborative consensus for optimized multilocus sequence typing of Candida albicans. Journal of Clinical Microbiology 41, 5265–5266.

2003 Bartizal, C., Odds, F.C. Influence of methodologic variables on susceptibility testing with caspofungin against Candida species and Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy 47, 2100-2107.

2002 MacCallum, D.M., Odds, F.C. Influence of grapefruit juice on itraconazole plasma levels in mice and guinea pigs. Journal of Antimicrobial Chemotherapy 50, 219–224.

Page 12 of 23

2002 MacCallum, D.M., Odds, F.C. Efficacy of parenteral itraconazole against disseminated Candida albicans infection in two mouse strains. Journal of Antimicrobial Chemotherapy 50, 225–229.

2002 Freydière, A.-M. Parant, F., Noel-Baron, F., Crepy, M., Treny, A., Raberin, H., Davidson, A., Odds, F.C. Identification of Candida glabrata by a 30-second trehalase test. Journal of Clinical Microbiology 40, 3602–3605.

2002 Badoc, C., De Meeus, T., Bertout, S., Odds, F. C., Maillie, M., Bastide, J. M. Clonality structure in Candida dubliniensis. FEMS Microbiology Letters 209, 249-254.

2001 Rambali, B., Fernandez, J.A., Van Nuffel, L., Woestenborghs, F., Baert, L., Massart, D.L., Odds, F.C. Susceptibility testing of pathogenic fungi with itraconazole: a process analysis of test variables. Journal of Antimicrobial Chemotherapy 48, 163–177.

2001 Parant F, Freydière A-M, Gille Y, Boiron P, Odds FC. Identification, en une minute, des colonies de Candida glabrata par détectation de la tréhalase. Journale de Mycologie Médicale 11, 26–31.

2001 Murad, A.M.A, Leng, P., Straffon, M., Wishart, J., Macaskill, S., MacCallum, D., Schnell, N., Talibi, D., Marechal, D., Tekaia, F., d’Enfert, C., Gaillardin, C., Odds, F.C., Brown, A.J.P. NRG1 represses yeast-hypha morphogenesis and hypha-specific gene expression in Candida albicans. The EMBO Journal 20, 4742–4752.

2001 Freydière, A.M., Odds, F.C. Commercial kits for yeast identification: concerns for standardization. European Journal of Clinical Microbiology & Infectious Diseases 20, 366–367.

2000 Saha, A.K., Liu, L., Simoneaux, R.L., Kukla, M.J., Marichal, P., Odds, F. Novel antifungals based on 4-substituted imidazole: a combinatorial chemistry approach to lead discovery and optimization. Bioorganic & Medicinal Chemistry Letters. 10, 2175–2178.

2000 Saha, A.K., Liu, L., Marichal, P., Odds, F. Novel antifungals based on 4-substituted imidazole: solid-phase synthesis of substituted aryl sulfonamides towards optimization of in vitro activity. Bioorganic & Medicinal Chemistry Letters. 10, 2735–2739.

2000 Odds, F.C., Vanden Bossche, H. Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro. Journal of Antimicrobial Chemotherapy 45, 371–374..

2000 Odds, F.C., Van Nuffel, L., Gow N.A.R. Survival in experimental Candida albicans infections depends on inoculum growth conditions as well as animal host. Microbiology 146, 1881–1889.

2000 Odds, F.C., Oris, M., Van Dorsselaer, P., Van Gerven, F. Activity of an intravenous formulation of itraconazole in experimental disseminated Aspergillus, Candida and Cryptococcus infections. Antimicrobial Agents and Chemotherapy 44, 3180–3183.

2000 Odds, F.C., Davidson, A. “Room temperature” use of CHROMagar Candida®. Diagnostic Microbiology and Infectious Disease 38, 147–150.

2000 De Backer, M.D., de Hoogt, R.A., Froyen, G., Odds, F.C., Simons, F., Contreras, R., Luyten, W.H.M.L. Single allele knock-out of Candida

Page 13 of 23

albicans CGT1 leads to unexpected resistance to hygromycin B and elevated temperature. Microbiology 146, 353–365.

1999 Overdijk, B., Van Steijn, G.J., Odds, F.C. Distribution of chitinase in guinea pig tissues and increases in levels of this enzyme after systemic infection with Aspergillus fumigatus. Microbiology 145, 259–269.

1999 Odds, F.C., Dupont, B., Rinaldi, M.G., Stevens, D.A., Warnock, D.W., Woestenborghs, R. Bioassays for itraconazole blood levels: an inter-laboratory collaborative study. Journal of Antimicrobial Chemotherapy 43, 723–727.

1999 Meis, J.F.G.M., Ruhnke, M., De Pauw, B.E., Odds, F.C., Seigert, W., Verweij, P.E. Candida dubliniensis candidemia in patients with chemotherapy induced neutropenia and bone marrow transplantation. Emerging Infectious Diseases 5, 150–153.

1999 Marichal, P., Koymans, L., Willemsens, S., Bellens, D., Verhasselt, P., Luyten, W., Borgers, M., Ramaekers, F.C.S., Odds, F.C., Vanden Bossche, H. Contribution of mutations in the cytochrome P450 14-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 145, 2701–2713.

1999 Marichal, P., Gorrens, J., Laurijssens, L., Vermuyten, K., Van Hove, C., Le Jeune, L., Verhasselt, P., Sanglard, D., Borgers, M., Ramaekers, F.C.S., Odds, F.C., Vanden Bossche, H. Accumulation of 3-ketosteroids induced by itraconazole in azole-resistant clinical Candida albicans isolates. Antimicrobial Agents and Chemotherapy 43, 2663–2670.

1998 Schoofs, A., Odds, F.C., Colebunders, R., Ieven, M., Goossens, H. Cross-sectional study of oral Candida carriage in HIV-seropositive population: predisposing factors, epidemiology and antifungal susceptibility. Mycoses 41, 203–211.

1998 Odds, F.C., Van Nuffel, L., Dams, G. Prevalence of Candida dubliniensis isolates in a yeast stock collection. Journal of Clinical Microbiology 36, 2869–2873..

1998 Odds, F.C., Van Gerven , F., Espinel-Ingroff, A., Bartlett, M.S., Galgiani, J.N., Ghannoum, M.A., Lancaster, M.V., Pfaller, M.A., Rex, J.H., Rinaldi, M.G., Walsh, T.J. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrobial Agents and Chemotherapy 42, 282–288.

1998 Hube B., Sanglard, D., Schaller, M., Ibrahim, A., Odds, F.C., Gow, N.A.R. Welche Funktionen heben sechs verscheidene Gene für sekretorische Proteinasen von Candida albicans? Mycoses 41 (suppl. 1), 47–50.

1998 Buurman, E.T., Westwater, C., Hube, B., Brown, A.J.P., Odds, F.C., Gow, N.A.R. Molecular analysis of CaMnt1p, a mannosyl transferase important for adhesion and virulence of Candida albicans. Proceedings of the National Academy of Sciences USA 95, 7670–7675.

1998 Arrese, J.E., De Doncker, P., Odds, F.C., Pierard, G.E. Reduction in the growth of non-dermatophyte moulds by itraconazole: evaluation by corneofungimetry assay. Mycoses. 41, 461–465.

Page 14 of 23

1997 Schoofs, A., Odds, F.C., Colebunders, R., Ieven, M., Wouters, L., Goossens, H. Isolation of Candida species on media with and without added fluconazole reveals high variability in relative growth susceptibility phenotypes. Antimicrobial Agents and Chemotherapy 41, 1625–1635.

1997 Schoofs, A., Odds, F.C., Colebunders, B., Ieven, G., Goossens, H. Recognition and identification of Candida dubliniensis isolates from HIV patients: use of specialized isolation media. European Journal of Clinical Microbiology and Infectious Diseases 16, 296–300.

1997 Sanglard, D., Hube, B., Monod, M., Gow, N.A.R., Odds, F.C. A triple deletion of the secretory aspartyl protease genes SAP4, SAP5, SAP6 causes attenuated virulence in Candida albicans. Infection and Immunity 65, 3539–3546.

1997 Rex, J.H., Pfaller, M.A., Galgiani, J.N., Bartlett, M.S., Espinel-Ingroff, A., Ghannoum, M.A., Lancaster, M., Odds, F.C., Rinaldi, M.G., Walsh, T.J., Barry, A.L. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clinical Infectious Diseases 24, 235–247.

1997 Reichard, U., Monod, M., Odds, F.C., Rüchel, R. Virulence of an aspergillopepsin-deficient mutant of Aspergillus fumigatus and evidence for another aspartic proteinase linked to the fungal cell wall. Journal of Medical and Veterinary Mycology 35, 189–196.

1997 Odds, F.C., Rinaldi, M.G., Cooper, C.R. Jr., Fothergill, A., Pasarell, L., McGinnis, M.R. Candida and Torulopsis: a blinded evaluation of use of pseudohypha formation as basis for identification of medically important yeasts. Journal of Clinical Microbiology 35, 313–316.

1997 Marichal, P., Vanden Bossche, H., Odds, F.C., Nobels, G., Warnock, D.W., Timmerman, V., Fay, S., Møse-Larsen, P. Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrobial Agents and Chemotherapy 41, 2229–2237.

1997 Hube, B., Sanglard, D., Odds, F.C., Hess, D., Monod, M., Schäfer, W., Brown, A.J.P., Gow, N.A.R. Disruption of each of the secretory aspartyl proteinase genes SAP1, SAP2 and SAP3 in Candida albicans attenuates virulence. Infection and Immunity 65, 3529–3538.

1997 Espinel-Ingroff, A., Bartlett, M., Bowden, R., Chin, N.X., Cooper, C.R., Jr., Fothergill, A., McGinnis, M.R., Menezes, P., Messer, S.A., Nelson, P.W., Odds, F.C., Pasarell, L., Peter, J., Pfaller, M.A., Rex, J.H., Rinaldi, M.G., Shankland, G., Walsh, T.J., Weitzmann, I. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. Journal of Clinical Microbiology 35, 139–143.

1996 Rex, J.H., Pfaller, M.A., Lancaster, M., Odds, F.C., Bolmström, A., Rinaldi, M.G. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of ketoconazole and itraconazole. Journal of Clinical Microbiology 34, 816–817.

1996 Pfaller, M.A., Messer, S.A., Bolmström, A, Odds, F.C., Rex, J.H. Multisite reproducibility of the Etest agar diffusion MIC method for antifungal

Page 15 of 23

susceptibility testing of yeast isolates. Journal of Clinical Microbiology 34, 1691–1693.

1996 Overdijk, B., Van Steijn, G.J., Odds, F.C. Chitinase levels in guinea pig blood are increased after systemic infection with Aspergillus fumigatus. Glycobiology 6, 627–634.

1996 Odds, F.C., Dams, G., Lewi, P. Susceptibilities of Candida species to antifungal agents visualized by two-dimensional relative growth scatterplots. Antimicrobial Agents and Chemotherapy 40, 588–594.

1996 De Doncker, P., Decroix, J., Piérard, G.E., Roelant, D., Woestenborghs, R., Jacqmin, P., Odds, F., Heremans, A/, Dockx, P/, Roseeuw, D. Antifungal pulse therapy in onychomycosis: a pharmacokinetic/pharmacodynamic evaluation of monthly cycles of 1 week pulse with itraconazole. Archives of Dermatology 132, 34–41.

1996 De Doncker, P., Decroix, J., Pierard, G.E., Roelant, D., Woestenborghs, R., Jacqmin, P., Odds, F., Heremans, A., Dockx, P., Roseeuw, D. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Archives of Dermatology 132, 34–41.

1995 Van Gerven, F., Odds, F.C. The anti-Malassezia furfur activity in vitro and in experimental dermatitis of six imidazole antifungal agents: bifonazole, clotrimazole, flutrimazole, ketoconazole, miconazole and sertaconazole. Mycoses 38, 389–393.

1995 Odds, F.C., Vranckx, L, Woestenborghs, F. Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation. Antimicrobial Agents and Chemotherapy 39, 2051–2060.

1995 Odds, F.C., De Backer, T., Dams, G., Vranckx, L., Woestenborghs, F. Oxygen as limiting nutrient for growth of Cryptococcus neoformans. Journal of Clinical Microbiology 33, 995-997.

1995 Louwagie, B.M-L., Surmont, I., Verhaegen, J., Odds F.C. Differential and enrichment media for selective culture and recognition of yeasts from clinical material. European Journal of Clinical Microbiology and Infectious Diseases 14, 406-411.

1995 Ginter, G., de Hoog, G.S., Pschaid, A., Fellinger, M., Bogiatzis, A., Berghold, C., Reich, E.M., Odds, F.C. Arthritis without grains caused by Pseudallescheria boydii. Mycoses 38, 369–371.

1994 Odds, F.C., Bernaerts, R. CHROMagar® Candida, a new, differential isolation medium for the presumptive identification of clinically important Candida species. Journal of Clinical Microbiology 32, 1923-1929.

1993 Odds, F.C., Baeten, B. Coremans, G. Van Cutsem, J. De Beule, K., Cauwenbergh, G. Clinical experiences with itraconazole in vaginal Candida infections. International Journal of Feto-Maternal Medicine 5, 147-149.

1993 Odds, F.C. Effects of temperature on anti-Candida activity of antifungal antibiotics. Antimicrobial Agents and Chemotherapy 37, 685-691.

1993 Fromtling, R.A., Galgiani, J.N., Pfaller, M.A., Espinel-Ingroff, A., Bartizal, K., Bartlett, M.S., Body, B.A., Frey, C. Hall, G. Roberts, G.D., Nolte, R., Odds, F.C., Rinaldi, M.G., Sugar, A.M., Villareal, K. Multicenter

Page 16 of 23

evaluation of a macrobroth antifungal susceptibility test for yeasts. Antimicrobial Agents and Chemotherapy 37, 39-45.

1992 Xhonneux, B., Jansen, T., Borgers, M., Odds, F.C. Effects of itraconazole on phagocytosis and killing of Candida glabrata by polymorphonuclear leukocytes from guinea pigs. Journal of Antimicrobial Chemotherapy 30, 181-188.

1992 Vanden Bossche, H., Marichal, P., Odds, F.C., Le Jeune, L., Coene, M.-C. Characterization of an azole-resistant Candida glabrata isolate. Antimicrobial Agents and Chemotherapy 36, 2602-2610.

1992 Sharp, A.M., Evans, E.G.V., Odds, F.C. Species and biotypes of Candida from neonates in a prospective study of a special care baby unit. Archives of Disease in Childhood 67, 48-52.

1992 Schmid, J., Odds, F.C., Wiselka, M.W., Nicholson, K.G., Soll, D.R. Genetic similarity and maintenance of Candida albicans strains from a group of AIDS patients, demonstrated by DNA fingerprinting. Journal of Clinical Microbiology 30, 935-941.

1992 Odds, F.C., Arai, T., DiSalvo, A.F., Evans, E.G.V., Hay, R.J., Randhawa, H.S., Rinaldi, M.G., Walsh, T.J. Nomenclature of fungal diseases: a report and recommendations from a Sub-Committee of the International Society for Human and Animal Mycology (ISHAM). Journal of Medical and Veterinary Mycology 30, 1-10.

1992 Odds, F.C. Antifungal susceptibility testing of Candida species by relative growth measurement at single concentrations of antifungal agents. Antimicrobial Agents and Chemotherapy 36, 1727-1737.

1992 Merson-Davies, L.A., Odds, F.C. Expansion of the Candida albicans cell envelope in different morphological forms of the fungus. Journal of General Microbiology 138, 461-466.

1991 Van Cutsem, J., Van Gerven, F., Cauwenbergh, G., Odds, F., Janssen, P.A.J. The anti-inflammatory effects of ketoconazole: a comparative study with hydrocortisone acetate in a model using living and killed Staphylococcus aureus on the skin of guinea-pigs. Journal of the American Academy of Dermatology 25, 257-261.

1991 Odds, F.C. Long-term preservation of pathogenic yeasts under distilled water. Journal of Medical and Veterinary Mycology 29, 413-415.

1991 Odds, F.C. A quantitative microculture system with standardized inocula for strain typing, susceptibility testing and other physiologic measurements with Candida albicans and other yeasts Journal of Clinical Microbiology 29, 2735-2740.

1991 Merson-Davies, L.A., Malet, R., Young, S., Riley, V.C., Schober, P., Fisk, P.G., Odds, F.C. Quantification of Candida albicans morphology in vaginal smears. European Journal of Obstetrics, Gynecology and Reproductive Biology 42, 49-52.

1991 Merson-Davies, L.A., Hopwood, V., Robert, R., Marot-Leblond, A., Senet, J.-M., Odds, F.C. Reaction of Candida albicans cells of different morphology index with monoclonal antibodies specific for the hyphal form. Journal of Medical Microbiology 35,.321-324.

Page 17 of 23

1991 Jansen, T.M., Van de Ven, M.A.A., Borgers, M., Odds, F.C., Van Cutsem, J. Fungal morphology after treatment with itraconazole as a single oral dose in experimental vaginal candidosis in rats. American Journal of Obstetrics and Gynecology 165, 1552-1557.

1991 Hube, B., Turver, C.J., Odds, F.C., Eiffert, H., Boulnois, G.J., Köchel, H., Rüchel, R. Sequence of the Candida albicans gene encoding the secretory aspartate proteinase. Journal of Medical and Veterinary Mycology 29, 129-132.

1991 Hube, B., Turver, C.J., Odds, F.C., Eiffert, H., Boulnois, G.J., Köchel, H., Rüchel, R. Identifizierung, Klonierung und Charakterisierung des Gens der sekretorischen Aspartat-Protease von Candida albicans . Mycoses 34 (suppl.), 59-61.

1991 Mackenzie, D.W.R., Odds, F.C. Non-identity and authentication of two major reference strains of Candida albicans. Journal of Medical and Veterinary Mycology 29, 255-261.

1990 Pfaller, M.A., Rinaldi, M.G., Galgiani, J.N., Bartlett, M.S., Body, B.A., Espinel-Ingroff, A., Fromtling, R.A., Hall, G.S., Hughes, C.E., Odds, F.C., Sugar, A.M. Collaborative investigation of variables in antifungal susceptibility testing of yeasts. Antimicrobial Agents and Chemotherapy 34, 1648-1654.

1990 Stevens, D.A., Odds, F.C., Scherer, S. Application of DNA typing methods to Candida albicans epidemiology and correlations with phenotype. Reviews of Infectious Diseases 12, 258-266.

1990 Odds, F.C., Sackin, M.J., Jones, D. Numerical taxonomic analysis of imperfect species in Candida and Torulopsis shows no basis for generic separation. Journal of General Microbiology 136, 761-765.

1990 Montague, W., Odds, F.C. Academic selection criteria and subsequent performance. Medical Education 24, 151-157.

1990 Fruit, J., Caillez, J.C., Odds, F.C., Poulain, D. Expression of an antigenic epitope by surface glycoproteins of Candida albicans: variability among species, strains and yeast cells of the genus Candida . Journal of Medical and Veterinary Mycology 28, 241-252.

1989 Odds, F.C., Webster, C.E., Fisk, P.G., Riley, V.C., Mayuranathan, P., Simmons, P.D. Candida species and C. albicans biotypes in women attending clinics in genitourinary medicine. Journal of Medical Microbiology 29, 51-54.

1989 Odds, F.C., Merson-Davies, L.A. Colony variations in Candida species. Mycoses 32, 275-282.

1989 Odds, F.C., Kibbler, C.C., Walker, E., Bhamra, A., Prentice, H.G., Noone, P. Carriage of Candida species and C. albicans biotypes in patients undergoing chemotherapy or bone marrow transplantation for haematological diseases. Journal of Clinical Pathology 42, 1259-1266.

1989 Odds, F.C., Auger, P., Krogh, P., Neely, A.N., Segal, E. Biotyping of Candida albicans: results of an international collaborative survey. Journal of Clinical Microbiology 27, 1506-1509.

1989 Odds, F.C. Antifungal action of saperconazole (R 66905) in vitro. Journal of Antimicrobial Chemotherapy 24, 533-537.

Page 18 of 23

1989 Merson-Davies, L.A., Odds, F.C. A morphology index for estimation of cell shape in Candida albicans. Journal of General Microbiology 135, 3143-3152.

1989 Kibbler, C.C., Odds, F.C. Fluconazole versus ketoconazole in oropharyngeal candidosis in AIDS. Lancet 1, 1130.

1989 Abbott, A.B., Odds, F.C. Abrogation by glucose of the ATP suppression induced by miconazole in Candida albicans. Journal of Antimicrobial Chemotherapy 24, 905-919.

1988 Page, S., Odds, F.C. Binding of plasma proteins to Candida species in vitro. Journal of General Microbiology 134, 2693-2702.

1988 Odds, F.C., Webster, C.E., Mayuranathan, P., Simmons, D. Candida concentrations in the vagina and their association with signs and symptoms of vaginal candidosis Journal of Medical and Veterinary Mycology 26, 277-282.

1988 Odds, F.C., Webster, C.E. Effects of azole antifungals in vitro on host/parasite interactions relevant to Candida infections. Journal of Antimicrobial Chemotherapy 22, 473-481.

1988 Odds, F.C. Standardization of MIC tests for antifungals against Candida species. In: J.M. Torres-Rodriguez (ed.) Proceedings of the X Congress of the International Society for Human and Animal Mycology-ISHAM, pp. 210-212. J.R. Prous, S.A., Barcelona.

1988 Odds, F.C. Activity of cilofungin (LY 121019) against Candida species in vitro. Journal of Antimicrobial Chemotherapy 22, 891-897.

1988 Neely, A.N., Odds, F.C., Basatia, B.K., Holder, I.A. Characterization of Candida isolates from pediatric burn patients. Journal of Clinical Microbiology 26, 1645-1649.

1987 Webster, C.E., Odds, F.C. Growth of pathogenic Candida isolates anaerobically and under elevated concentrations of CO2 in air. Journal of Medical and Veterinary Mycology 25, 47-53.

1987 Odds, F.C., Webster, C.E., Riley, V.C., Fisk, P.G. Epidemiology of vaginal Candida infection: significance of numbers of vaginal yeasts and their biotypes. European Journal of Obstetrics, Gynecology and Reproductive Biology 25, 53-66.

1987 Odds, F.C., Palacio-Hernanz, A., Cuadra, J., Sanchez, J. Disseminated Candida infection syndrome in heroin addicts - dominance of a single Candida albicans biotype. Journal of Medical Microbiology 23, 275-277.

1987 Miro, J.M., Puig de la Bellacasa, J., Odds, F.C., Gill, B.K., Bisbe, J., Gatell, J.M., Gonzalez, J., Latorre, X., Jiminez de Anta, M.T., Soriano, E., Garcia San Miguel, J. Systemic candidiasis in Spanish heroin addicts: a possible source of infection. Journal of Infectious Diseases 156, 857-858.

1987 Miro, J.M., Palacio Hernanz, A., Martinez Ortiz de Zarate, M., de la Cuadra, J., Odds, F.C. Predominio de Candida albicans serotipo A, biotip 153/7 en los brotes de candidiasis diseminada en heroinomanos en Espana. Medicina Clinica 89, 38.

1986 Sevilla, M.-J., Odds, F.C. Development of Candida albicans hyphae in different growth media - variations in growth rates, cell dimensions and

Page 19 of 23

timing of morphogenetic events. Journal of General Microbiology 132, 3083-3088.

1986 Sevilla, M.-J., Odds, F.C. Consistency of protein patterns in Candida albicans during hyphal septum and branch formation. Journal of Medical and Veterinary Mycology 24, 419-422.

1986 Riley, V.C., Odds, F.C., Fisk, P.E., Webster, C.E. Finger nails as a reservoir for Candida albicans in recurrence of vaginal candidosis. Genitourinary Medicine 62, 358.

1986 Odds, F.C., Cheesman, S.L., Abbott, A.B. Antifungal effects of fluconazole (UK 49858), a new triazole antifungal, in vitro. Journal of Antimicrobial Chemotherapy 18, 473-478.

1986 Odds, F.C., Abbott, A.B., Pye, G., Troke, P.F. Improved method for estimation of azole antifungal inhibitory concentrations against Candida species, based on azole/antibiotic interactions. Journal of Medical and Veterinary Mycology 24, 305-311.

1985 Polak, A., Odds, F.C., Ludin, E., Scholer, H.J. Correlation of susceptibility test results in vitro with response in vivo: ketoconazole therapy in a systemic candidiasis model. Chemotherapy 31, 395-404.

1985 Odds, F.C., Cockayne, A., Hayward, J., Abbott, A.B. Effects of imidazole- and triazole-derivative antifungal compounds on the growth and morphological development of Candida albicans hyphae. Journal of General Microbiology 131, 2581-2589.

1985 Odds, F.C., Cheesman, S.L., Abbott, A.B. Suppression of ATP in Candida by imidazole- and triazole-derivative antifungal agents. Sabouraudia: Journal of Medical and Veterinary Mycology 23, 415-424.

1985 Burnie, J.P., Odds, F.C., Lee, W., Webster, C., Williams, J.D. Outbreak of systemic Candida albicans in intensive care unit caused by cross infection. British Medical Journal 290, 746-748.

1985 Burnie, J.P., Matthews, R.C., Lee, W., Odds, F.C., Williams, J.D. Control of an outbreak of systemic Candida albicans. British Medical Journal 291, 1092.

1985 Anderson, M.L., Odds, F.C. Adherence of Candida albicans to vaginal epithelia: significance of morphological form and effect of ketoconazole. Mykosen 28, 531-540.

1984 Working Group of the British Society for Mycopathology. Laboratory methods for flucytosine (5-fluorocytosine). Journal of Antimicrobial Chemotherapy 14, 1-8.

1984 Odds, F.C., Webster, C.E., Abbott, A.B. Antifungal relative inhibition factors: BAY l-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents. Journal of Antimicrobial Chemotherapy 14, 105-114.

1984 Odds, F.C., Abbott, A.B. Relative inhibition factors - a novel approach to the assessment of antifungal antibiotics in vitro. Journal of Antimicrobial Chemotherapy 13, 31-43.

1984 Odds, F.C. Demonstration of a septal pore in yeast cells of Candida albicans. Sabouraudia: Journal of Medical and Veterinary Mycology 22, 505-507.

Page 20 of 23

1984 Cockayne, A., Odds, F.C. Interactions of Candida albicans yeast cells, germ tubes and hyphae with human polymorphonuclear leukocytes in vitro. Journal of General Microbiology 130, 465-471.

1983 Odds, F.C., Ryan, M.D., Sneath, P.H.A. Standardization of antigens from Aspergillus fumigatus. Journal of Biological Standardization 11, 157-162.

1983 Odds, F.C., Abbott, A.B., Stiller, R.L., Scholer, H.J., Polak, A., Stevens, D.A. Analysis of Candida albicans phenotypes from different geographical and anatomical sources. Journal of Clinical Microbiology 18, 849-857.

1983 Odds, F.C., Abbott, A.B., Reed, T.A.G., Willmott, F.E. Candida albicans strain types from the genitalia of patients with and without Candida infection. European Journal of Obstetrics and Gynecology 15, 37-43.

1983 Odds, F.C., Abbott, A.B. Modification and extension of tests for differentiation of Candida species and strains. Sabouraudia 21, 79-81.

1983 Macdonald, F., Odds, F.C. Virulence for mice of a proteinase-secreting strain of Candida albicans and a proteinase-deficient mutant. Journal of General Microbiology 129, 431-438.

1982 Odds, F.C. Ketoconazole resistance. The Lancet ii, 771.1982 Odds, F.C. Interactions among amphotericin B, 5-fluorocytosine, ketoconazole

and miconazole against pathogenic fungi in vitro. Antimicrobial Agents and Chemotherapy 22, 763-775.

1982 Odds, F.C. Genital candidosis. Clinical and Experimental Dermatology 7, 345-354.

1981 Odds, F.C., Macdonald, F. Persistence of miconazole in vaginal secretions after single applications of the antifungal: implications for the treatment of vaginal candidosis. British Journal of Venereal Diseases 57, 400-401.

1981 Odds, F.C. Persistence of miconazole in saliva after a single oral dose. Clinical Research Reviews 1, 231-232.

1980 Odds, F.C., Gentles, J.C., Milne, L.J.R., Ball, E.H. Activity in vitro and in vivo of a new imidazole antifungal, ketoconazole. Journal of Antimicrobial Chemotherapy 6, 97-104.

1980 Odds, F.C., Evans, E.G.V. Distribution of pathogenic yeasts and humoral antibodies to Candida among hospitalized patients. Journal of Clinical Pathology 33, 750-756.

1980 Odds, F.C., Abbott, A.B. A simple system for the presumptive identification of Candida albicans and differentiation of strains within the species. Sabouraudia 18, 301-318.

1980 Odds, F.C. Laboratory evaluation of antifungal agents: a comparison of five imidazole derivatives of clinical importance. Journal of Antimicrobial Chemotherapy 6, 749-761.

1980 Macdonald, F., Odds, F.C. Inducible proteinase of Candida albicans in diagnostic serology and in the pathogenesis of systemic candidosis. Journal of Medical Microbiology 13,423-435.

1980 Macdonald, F., Odds, F.C. Purified Candida albicans proteinase in the serological diagnosis of systemic candidosis. Journal of the American Medical Association 243, 2409-2411.

Page 21 of 23

1980 Clarke, M., Davies, D.P., Odds, F.C., Mitchell, C. Neonatal systemic candidiasis treated with miconazole. British Medical Journal 2, 354.

1979 Odds, F.C. Problems in the laboratory assessment of antifungal activity. Postgraduate Medical Journal 55, 677-680.

1978 Taylor, C.F., Watkins, J.D., Odds, F.C., Gough, D.A. A comparative study of the effectiveness of two antifungal agents in treating athlete's foot. British Journal of Clinical Practice (spl.) 8-12.

1978 Odds, F.C., Hall, C.A., Abbott, A.B. Peptones and mycological reproducibility. Sabouraudia 16, 237-246.

1978 Odds, F.C., Evans, E.G.V., Taylor, M.A.R., Wales, J.K. Prevalence of pathogenic yeasts and humoral antibodies to Candida in diabetic patients. Journal of Clinical Pathology 3, 840-844.

1977 Odds, F.C. Cure and relapse with antifungal therapy. Proceedings of the Royal Society of Medicine 20 (spl. 4), 24-28.

1975 Odds, F.C., Evans, E.G.V., Holland, K.T. Detection of Candida precipitins. A comparison of double diffusion and counter-immuno–electrophoresis. Journal of Immunological Methods 7, 211-218.

1975 Odds, F.C., Evans, E.G.V. Routine use of a modified Sabouraud's dextrose broth in the germ tube test for Candida albicans. Medical Laboratory Technology 32, 23-36.

1975 Evans, E.G.V., Odds, F.C., Holland, K.T. Resistance of the Candida albicans filamentous cycle to environmental change. Sabouraudia 13, 231-238.

1975 Evans, E.G.V., Odds, F.C., Holland, K.T. Optimum conditions for initiation of filamentation in Candida albicans. Canadian Journal of Microbiology 21, 338-342.

1974 Odds, F.C., Trujillo-Gonzalez, A. Acid phosphatase levels in the genus Candida and their application to the taxonomy and identification of Candida species. Sabouraudia 12, 287-294.

1974 Odds, F.C., Kaufman, L., McLaughlin, D., Callaway, C., Blumer, S.O. Effect of chitinase complex and beta-1:3-glucanase on the antigenicity and chemistry of yeast-form cells and other fractions of Histoplasma capsulatum and Blastomyces dermatitidis. Sabouraudia 12, 138-149.

1974 Evans, E.G.V., Odds, F.C., Richardson, M.D., Holland, K.T. The effect of growth medium on filament production in Candida albicans. Sabouraudia 12, 112-119.

1973 Odds, F.C., Hierholzer, J.C. Purification and properties of a glycoprotein acid phosphatase from Candida albicans. Journal of Bacteriology 114, 257-266.

1973 Odds, F.C. Spirolaterals. The Mathematics Teacher 66, 121-124.1973 Evans, E.G.V., Richardson, M.D., Odds, F.C., Holland, K.T. Relevance of

antigenicity of Candida albicans growth phases to diagnosis of systemic candidiasis. British Medical Journal 4, 86-87.

1973 Chattaway, F.W., Bishop, R., Holmes, M.R., Odds, F.C., Barlow, A.J.E. Enzyme activities associated with carbohydrate synthesis and breakdown in the yeast and mycelial forms of Candida albicans. Journal of General Microbiology 75, 97-109.

Page 22 of 23

1971 Chattaway, F.W., Odds, F.C., Barlow, A.J.E. An examination of the production of hydrolytic enzymes and toxins by pathogenic strains of Candida albicans. Journal of General Microbiology 67, 255-263.

1969 Chattaway, F.W., Hullin, R.P., Odds, F.C. The variability of creatinine excretion in normal subjects, mental patients and pregnant women. Clinica Chimica Acta 26, 567-576.

Patents/Patent Applications2005 Vernier, D.F.J., Odds, F.C., Gestel, J.F.E., Guillemont, J.E.G., Venet,

M.G., Poignet, H.J.J., Decrane, L.F.B. quinoline derivatives and their use as mycobacterial inhibitors. Patent No. WO2004011436

2004 Van Der Veken, L.J.E., Vanden Bossche, H.F.A., Heeres, J., Meerpoel, L., Odds, F.C. 2,4,4-Trisubstituted-1-3-dioxolanes with antimycotic effect. Patent no. BG64314.

2004 De Doncker, P.R.G., Odds , F.C., Ho, K., Cauwenbergh, G.F.M., Fernandez Candelario, A. Body and or hair cleansing composition and process for preparing such composition. Patent no. CZ293585.

2003 Backx, L.J.J., Heeres, J., Meerpoel, L., Van Der Veken, L.J.E., Odds, F.C. Water soluble azoles as broad-spectrum antifungals. Patent no. SI1077976T.

2002 Backx, L.J.J., Van Der Eycken, L.A.L., Mesens, J.L., Heeres, J., Odds, F.C. Watersoluble azole antifungals. Patent no. CY2176.

2000 Meerpoel, L.; Heeres, J., Odds, F.C,. Vanden Bossche, H.F.A., Van der Veken, L.J.E.. 2,4,4-trisubstituted-1,3-dioxolane antifungals. US Patent no. 6,387,906, application no. 462588. World patent no. WO99/02523.

2000 Meerpoel, L., Backx, L.J.J., Van der Veken, L.J.E., Heeres, J., Odds, F. Water soluble azoles as broad-spectrum antifungals. US Patent no. 6,384,030 , application no. 700251. World patent no. WO99/58530. European patent no. EE4311.

1999 Heeres, J., Meerpoel, L. Odds, F.C., Van Der Veken, L.J.E., Vanden Bossche, H.F.A. 2,4,4-trisubstituted-1,3-dioxolane antifungals. Patent no CA2295090.

1999 Embrechts, R.C.A., Odds, F.C., De Doncker, P.R.G. compositions containing an antifungal and a phospholipid. US Patent application no. 20020058059. World patent application no. 97201101.9.

1998 Odds, F.C., Ho, K.L., Cauwenbergh, G.F., Fernandez Candelario, A. Methods for using compositions containing dichlorophenyl imidazoldioxolan to treat seborrheic dermatitis, dandruff, psoriasis, and acne, and compositions thereof. Patent no. CA2294804.

1998 Odds, F.C., Embrechts, R.C.A., De Doncker, P, Gudula, R. Compositions containing an antifungal and a cationic agent. US Patent no. 6,207,142, application no. 403057. World patent no. WO98/46207. Patent no. DE69806577T.

1998 Odds, F.C., De Doncker, P.R.G., Ho, K., Fernandez Candelario, A., Cauwenbergh, G.F.M. Compositions containing an antifungal and a sulfur compound. Patent no. WO9729733.

1997 Heeres, J., Mostmans, J.H., Van Der Eycken, L.A.L., Odds, F.C., Stokbroekx, R.A., Van der Aa, M.J.M. Substituted azolone derivatives [with anti-Helicobacter activity]. US Patent no. 5,650,411, application no. 491960. World patent no. WO94/18978.

Page 23 of 23

1996 Venet, M.G., Guillemont, J.E.G., Vernier, D.F.J., Odds, F.C. 4-quinolinyl derivatives with anti-Helicobacter activity. US Patent no. 5,589,484 , application no. 428176. World patent no. WO94/10164.

1995 Heeres, J., Backx, L.J.J., Van der Eycken, L.A.L. Odds, F.C., Mesens, J.L. Watersoluble azole antifungals. US Patent no. 5,707,977, application no. 666270. World patent no. WO95/19983.

1994 Venet, M.G., Guillemont, J.E.G., Vernier, D.F.J., Odds, F.C. 4-quinolinyl derivatives. US Patent no. 5,589,484, application no. 428176. World patent no. WO94/10164.

1994 Odds, F.C., Venet, M.G., Guillemont, J.E., Vernier, D.F.J. 4-quinolinyl derivatives with anti-Helicobacter activity. Patent no. CA2146651.

1994 Heeres, J., Mostmans, J.H., Van Der Eycken, L.A.L. Odds, F.C., Stokbroekx, R.A., Van der Aa, M.J.M. Substituted azolone derivatives. US Patent no. 5,650,411, application no. 491960. World patent no. WO94/18978.